Quzyttir is a drug owned by Jdp Therapeutics Llc. It is protected by 5 US drug patents filed in 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 28, 2030. Details of Quzyttir's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8314083 | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | Active |
| US8263581 | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | Active |
| US9180090 | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | Active |
| US8513259 | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | Active |
| US9119771 | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Quzyttir's patents.
Latest Legal Activities on Quzyttir's Patents
Given below is the list of recent legal activities going on the following patents of Quzyttir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 May, 2024 | US8314083 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 Feb, 2024 | US8263581 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Feb, 2023 | US9119771 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Apr, 2021 | US9119771 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Apr, 2021 | US8314083 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Apr, 2021 | US8513259 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 15 Jan, 2021 | US8513259 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 15 Apr, 2020 | US8314083 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Apr, 2020 | US8263581 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 15 Apr, 2020 | US8263581 |
FDA has granted several exclusivities to Quzyttir. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Quzyttir, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Quzyttir.
Exclusivity Information
Quzyttir holds 1 exclusivities. All of its exclusivities have expired in 2022. Details of Quzyttir's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 04, 2022 |
US patents provide insights into the exclusivity only within the United States, but Quzyttir is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Quzyttir's family patents as well as insights into ongoing legal events on those patents.
Quzyttir's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Quzyttir's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 28, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Quzyttir Generic API suppliers:
Cetirizine Hydrochloride is the generic name for the brand Quzyttir. 47 different companies have already filed for the generic of Quzyttir, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Quzyttir's generic
Alternative Brands for Quzyttir
Quzyttir which is used for the treatment of acute urticaria and angioedema by increasing peak plasma concentration through intravenous injection., has several other brand drugs using the same active ingredient (Cetirizine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Harrow Eye |
| |||
| J And J Consumer Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Cetirizine Hydrochloride, Quzyttir's active ingredient. Check the complete list of approved generic manufacturers for Quzyttir
About Quzyttir
Quzyttir is a drug owned by Jdp Therapeutics Llc. It is used for the treatment of acute urticaria and angioedema by increasing peak plasma concentration through intravenous injection. Quzyttir uses Cetirizine Hydrochloride as an active ingredient. Quzyttir was launched by Jdp in 2019.
Approval Date:
Quzyttir was approved by FDA for market use on 04 October, 2019.
Active Ingredient:
Quzyttir uses Cetirizine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Cetirizine Hydrochloride ingredient
Treatment:
Quzyttir is used for the treatment of acute urticaria and angioedema by increasing peak plasma concentration through intravenous injection.
Dosage:
Quzyttir is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG/ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |